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Abstract While surgery remains the ﬁrst-line treatment
of most aggressive pituitary adenomas, medical therapy is
important as second-line or adjunctive therapy in a large
proportion of patients. Dopamine agonists (DAs) are the
best treatment for prolactinomas, but when DAs are not
tolerated, new somatostatin receptor subtype 5 (SSTR5)
inhibitors may offer an alternative in the future. Unfortu-
nately, these are unlikely to be effective in DA-resistant
prolactinomas. In acromegaly, the existing somatostatin
analogs, octreotide and lanreotide, will remain the medical
treatment of choice for the foreseeable future. There is an
urgent need for medical therapies in Cushing’s disease, and
the SSTR5 analogs could offer an effective treatment in a
proportion of patients within the next few years. Finally,
the medical management options for non-functioning
pituitary adenomas are also very limited, and a new chi-
meric agent with activity towards dopamine receptors,
SSTR5 and SSTR2 may help reduce adenoma recurrence in
the future.
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Introduction
Aggressive pituitary tumors are difﬁcult to manage. A wide
range of treatments are used including transsphenoidal
surgery (and transcranial surgery when the lesions occur
mainly outside the sella), dopamine agonists (DAs) for
prolactinomas and somatostatin analogs (SSAs) for other
types of adenomas, radiotherapy as third-line treatment,
and chemotherapy in some rare aggressive tumors, and
sometimes a combination of these treatment modalities is
required to control the tumor growth and recurrence.
However, improvements in the management of these
tumors are needed, and in particular for the treatment of
aggressive tumors. In this short paper we review some
promising medical therapies for the different types of
pituitary tumors.
Prolactinomas
The vast majority of prolactinomas, including invasive
macro-adenomas, are adequately controlled with dopamine
agonists (DAs). There are three potential receptor targets for
drug therapy of prolactinomas—DA2 receptors, somato-
statin receptors subtypes 2 and 5 (SSTR2 and SSTR5), and
estrogen receptors (E2-R). The DA2 receptors are expressed
in almost all prolactinomas and are the target for much
current therapy, but some patients are resistant to DA and
many do not tolerate DA therapy.
SSTR are expressed in prolactinomas, but the majority
express SSTR5 and not SSTR2 [1]. When quantiﬁed,
SSTR5 mRNA was detected at 40-fold higher concentra-
tions than SSTR2 mRNA (SSTR1 was also expressed in
prolactinomas but the signiﬁcance of this is not known) [1].
This expression pattern means that established somato-
statin analogs (SSAs) such as octreotide and lanreotide that
bind primarily to SSTR2 are ineffective in suppressing
prolactin secretion from these adenomas [2]. This has been
demonstrated by comparing the inhibition of prolactinomas
by octreotide and the experimental compound pasireotide
S. W. J. Lamberts (&)  L. J. Hoﬂand
Department of Internal Medicine, Division of Endocrinology,
Erasmus Medical Center, 230’s Gravendijkwal, 3015 CE
Rotterdam, The Netherlands
e-mail: s.w.j.lamberts@erasmusmc.nl
123
Pituitary (2009) 12:261–264
DOI 10.1007/s11102-008-0154-y(SOM-230), which has 40-fold greater binding afﬁnity to
SSTR5 than octreotide. This study showed slight inhibition
of prolactin secretion in one out of three adenomas by
octreotide, while pasireotide signiﬁcantly inhibited pro-
lactin secretion in all three adenomas [2]. Unfortunately,
potent SSTR5 inhibitors may not be of value in treating
prolactinomas, because their potential efﬁcacy is most
needed for treating DA-resistant prolactinomas, and most
of these prolactinomas appear to express no (or low levels)
of SSTR5 and are also resistant to SSAs that bind to this
receptor (Fig. 1)[ 1]. Furthermore, there was no additive
effect on prolactin secretion when a SSTR5 inhibitor was
added to a DA [1].
Prolactinomas also express estrogen receptors (E2-R)
[3], and the frequency of this observation is similar in men
and women (in a small-scale analysis, 60% of tumors from
men were E2-R-positive and 67–90% from women were
E2-R-positive) [4]. In vitro studies have been inconclusive
on the effects of selective E2-R modulators on prolactino-
mas [5]. Furthermore, the incidence of E2-R on recurrent
prolactinoma tumors was signiﬁcantly reduced (P = 0.03)
[4], and this suggests that DA-resistant adenomas would be
resistant to anti-estrogens.
Other potential therapies for prolactinomas (such as
gene therapy, molecular therapeutics or the use of nerve
growth factor) are in the very early stages of discovery [5].
Acromegaly
Although pegvisomant treatment normalises insulin-like
growth factor (IGF)-1 in a high proportion of patients with
acromegaly [6], it has no effect on tumor size, and SSAs
remain the ﬁrst-choice medical therapy for acromegaly,
especially in large and/or aggressive tumors.
Virtually all acromegaly tumors express both SSTR5
and SSTR2 (and a smaller proportion express SSTR1 or
SSTR3)[ 2]. In theory, molecules that bind to both SSTR5
and SSTR2 may provide improved efﬁcacy in acromegaly
(existing SSAs bind most potently to SSTR2). However,
measurements of apoptosis in somatotroph tumor cells
have shown that octreotide and a super-selective SSTR2
analog promote apoptosis to a similar degree, while a
super-selective SSTR5 analog is ineffective (Fig. 2)[ 7].
Both analogs did arrest growth, measured by an increase in
p27 and decrease in cyclin D1 expression, and so both
receptors appear to be involved in the cytostatic action of
SSAs [7]. The most important tumor shrinking effects of
SSAs appear, therefore, to be caused by binding to the
SSTR2, and agents with combined SSTR5 and SSTR2
binding are unlikely to be more effective. In tumors that are
resistant to octreotide or lanreotide, SSTR5 activation by
pasireotide may, in a minority of patients, further lower GH
and IGF-1 levels. With the expression of other SSTR
subtypes in a proportion of acromegaly tumors, and with
suggestions that apoptosis may also be mediated through
these other receptor subtypes [8], future SSTR3 analogs
may be useful in a small proportion of unresponsive cases.
Cushing’s disease
Surgery is the treatment of choice for most patients with
Cushing’s disease, but when surgery fails to control the
disease,therearenoproveneffectivemedicaltreatments[9].
Corticotropinomas often express dopamine receptors
and/or SSTR5. In Nelson’s syndrome (Cushing’s disease
treated with total adrenalectomy, in which pituitary
expansion occurs and ACTH levels increase), treatment
with the DA cabergoline has been shown to normalize
plasma adrenocorticotrophin (ACTH) levels and eliminate
the tumor within 1 year, but only when the dose of
cabergoline was increased to 2 mg/week [10]. When
cabergoline was withdrawn, ACTH levels increased [10].
In addition, many years ago, infusion of somatostatin was
also shown to reduce plasma ACTH in ﬁve patients with
Nelson’s syndrome by approximately 50% [11], and SSAs
may also reduce ACTH level and improve symptoms in
these patients [12].
However, in the majority of patients with Cushing’s
disease who do not have Nelson’s syndrome, the
Fig. 1 Effect of SSTR5-speciﬁc analog on prolactin secretion from
DA-susceptible and DA-resistant human prolactinomas. From Jaquet
et al. [1]
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123administration of octreotide had no beneﬁcial effect on
ACTH levels, tumor volume or symptoms [12, 13]. This is
because most tumors express mainly SSTR5 and not
SSTR2—demonstrated by the in vitro minor inhibition of
ACTH release (decrease of 28%) by octreotide in one out
of ﬁve tumors, and the greater reduction of ACTH release
(by 30–40%) by pasireotide in three out of ﬁve tumors [14].
A second study conﬁrmed the ACTH suppressing effects of
pasireotide (suppressed ACTH release by 23–56% in ﬁve
out of six tumor cell cultures) and showed suppression of
cell proliferation of 10–70% [15]. These preclinical results
suggest a possible role for SSTR5 analogs in the treatment
of some patients with Cushing’s disease, but clearly, clin-
ical studies are needed. Preliminary clinical data have
reported decreases in free urinary cortisol in patients with
de novo or persistent/recurrent Cushing’s disease after
pasireotide administration [9].
Expression of DA2 receptors and SSTR5 are expressed
similarly in micro- and macro-adenomas. However, recent
work shows that the subgroup of largest corticotroph ade-
nomas (Wilson and Hardy classiﬁcation Stage III–IV)
showed a near-complete loss of somatostatin and dopamine
receptor expression [16], so other treatment options are still
needed for these aggressive adenomas.
Retinoic acid has been shown to inhibit corticotroph
tumor growth and ACTH release in experimental Cush-
ing’s disease (probably via inhibition of the transcription
factors Ap-1 and Nur7 [7, 17] but the potential clinical
value of this agent has not been determined.
To date, surgery and radiotherapy remain the treatments
of choice for Cushing’s disease, and while agents with
combined SSTR5 and SSTR2 binding activity could pro-
vide a useful medical therapy for non-responsive or
recurring adenomas, their efﬁcacy is not yet proven.
Non-functioning pituitary adenomas
Non-functioning pituitary adenomas (NFPA) represent
approximately one-third of pituitary tumors. Transsphenoi-
dal surgery is the ﬁrst-line treatment, but removal of the
tumor is incomplete in approximately 50% of these adeno-
mas—many NFPA progress to macroadenomas before they
are detected, as the ﬁrst symptoms are often compressive
symptoms. Treatment with bromocriptine or octreotide has
been relatively unsuccessful in producing tumor shrinkage
[18, 19], and so medical therapies are still sought to prevent
regrowth of the tumor after partial removal by surgery.
As with many other adenomas described here, NFPA
express dopamine receptors and somatostatin receptors—in
the case of NFPA, SSTR2 and SSTR3 are frequently
expressed. Therefore, a new chimeric agent (BIM-23A760;
dopastatin) has been developed with activity towards
dopamine receptors and somatostatin receptors (speciﬁ-
cally, SSTR2 and SSTR5). This agent inhibited [
3H]-
thymidine uptake (a measure of cell growth) in 60% of
NFPA cell cultures (mean decrease of 33.6%) tested [20].
Inhibition with dopastatin was of a similar magnitude to
inhibition with a combination of cabergoline and octreotide
(Fig. 3). Furthermore, when an inhibitor of dopamine
activity was added in these experiments, dopastatin still
had an inhibitory effect on NFPA cells (but this was par-
tially inhibited to about 50% of the effect). This shows that
the effects of dopastatin on NFPA are mediated by binding
to both the dopamine and the somatostatin receptors [20].
No markers for response to dopastatin were identiﬁed in
this study [20].
The development of such chimeric molecules is an
exciting development in the treatment of NFPA, and the
results of future clinical trials are awaited with interest.
Conclusions
In prolactinomas, SSAs do not appear to offer any addi-
tional beneﬁt to treatment with DAs and are likely to be
ineffective in DA-resistant tumors. Selective agents for
SSTR5 may be useful in the future for patients that do not
tolerate DA therapy, but other medical therapies that could
replace or enhance treatment with DAs are many years
away. In acromegaly, medical therapy with the existing
SSAs and pegvisomant is excellent. Future studies may tell
Fig. 2 Pro-apoptotic effects of different somatostatin analogs in
human somatotroph tumors. From Ferrante et al. [7]
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123us if SSTR5 analogs will improve on the efﬁcacy of
currently available agents. SSTR5 analogs, alone or in
combination with DAs, may play a role in the future
medical management of Cushing’s disease, but not in the
most aggressive tumors, and ongoing trials may elucidate
the future role of such agents. Until then, surgery and
radiotherapy will remain the mainstay of treatment for
these tumors. In NFPA, there is a real need for effective
medical therapies, and the new chimeric DA-SSA dopast-
atin is an exciting development that, if proven in the clinic,
could become a very important tool in the management of
NFPA. The precise place of such chimeric agents in the
future treatment of NFPA is not known but initially they
may be most useful as a post-operative adjunct, especially
when there are suspected tumor remnants.
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